Researchers have discovered a key reason some cancer patients relapse after receiving chimeric antigen receptor T-cell ...

Dr Dinesh Pendharkar highlights how CAR T–cell therapy is reshaping cancer care in India by equipping the immune system with ...

In recent years, CAR-T cell therapy has revolutionized the treatment of patients with so-called ‘relapsed or refractory (r/r)’ aggressive B-cell lymphomas – i.e. lymphoma defined by disease ...

The Food and Drug Administration has announced new guidelines that will make CAR T-cell therapy more accessible to cancer ...

A research team has discovered a previously unknown mechanism that could explain why many patients with aggressive B-cell lymphoma do not respond to CAR-T cell therapy in the long term. The ...

Olalekan O. Oluwole discusses how CAR T-cell therapy is used to treat high-risk hematologic malignancies like lymphoma and ...

Explore the latest advancements in immunotherapies for T-cell lymphoma, addressing unique challenges and promising new treatment options.

During a live event, Priyanka Pophali, MD, MBBS, discussed CAR T-cell therapy referrals, timing, and challenges in relapsed ...

Mayo Clinic researchers say they have identified why some cancer patients relapse after receiving CAR-T cell therapy. The study, published in Molecular Cancer, reveals that the engineered immune cells ...

Mark Daniels, 83, says CAR T-cell therapy and strong support helped him overcome lymphoma twice and return to the ...

AbbVie gains control of an in vivo CAR-T therapy that could overcome limitations with currently approved autologous ...